Arsenault BJ, et al. - This study assessed the effect of lipid-lowering treatments on circulating PCSK9 and Lp[a]. Findings revealed a positive and dose dependent correlation of PCSK9 and Lp(a) with atorvastatin dosage in patients at high cardiovascular disease risk, while, higher PCSK9 but lower Lp(a) levels were seen in association with type 2 diabetes (T2D) mellitus presence. Also, it was demonstrated that cholesterol ester transfer protein (CETP) inhibition with torcetrapib slightly increased PCSK9 levels and decreased Lp(a) levels.